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Introduction
Nuclease based gene-editing techniques (Cas9/ZFN/TALEN -CaZiTa) introduce a double stranded break at a specified location with the guide of DNA-binding proteins (ZFN/TALEN) or RNA (CRISPR) 1 . Delivery within cells is a critical step for such gene-therapies 2 . The ability of recombinant adenoassociated virus (rAAV) to enter cells makes it a perfect choice as a vector for gene therapy 3 . A plasmid comprising the rAAV, CaZiTa, guide RNAs (for CRISPR), etc. is expected to enter the cell, edit, and remain episomal 4 . However, the rather obvious danger of integration of the plasmid into the genome is ignored. A recent pre-print 5 has highlighted that bacterial genes from the template plasmid (pCR2.1-TOPO) has integrated into bovine genomes 6 .
Recently, Massachusetts General Hospital published data on CRISPR edits (Accid:PRJNA563918), and concluded that 'AAV integration should be recognised as a common outcome for applications that utilize AAV for genome editing' 7 . However, there was no report of Cas9 integration. Here, data showing Cas9 integrating in the exact edit sites is shown. The same caveat applies to all three CaZiTa gene-therapies 1 .
Methods
Sequencing data was obtained from BioProject accession number, PRJNA563918, using SRA download tools (https:// github.com/ncbi/sra-tools/wiki). This project aims at finding "the genomic consequences of transduction with AAV vectors encoding CRISPR-Cas nucleases" 7 .
The reads were uniquified, split into open-reading frames using the getorf (version:6.6.0.0) program from the EMBOSS suite (http://emboss.sourceforge.net/download/) 8 .
Command: "getorf -find 1 -sequence <infile> -outseq <output> -minsize 10".
Exact 10-kmer were aligned to the Cas9 protein (Accid: AGZ01981.1, 1417aa). Subsequently, these reads were then aligned to the gene of interest -TMC1(Accid:NG_008213.1) or DMD(Accid:NM_001314034.1). The online BLAST interface using the default settings (https://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to generate images of integration with the genes of interest 9 . The number of reads with integration is conservative, since reads with less than a 10-kmer match were ignored. The AAV genome used was Accid:MK163936.1. Sequences that integrate Cas9/AAV with TMC1 and DMD are provided in Extended data: TMC1.cas9.fa/TMC1.aav.fa and DMD.cas9.fa/DMD.aav.fa, respectively.
Results and discussion
Cas9 integration in transmembrane channel like 1 (TMC1) TMC1, a transmembrane protein, is required for proper functioning of cochlear hair cells, and has been implicated in hearing loss and prelingual deafness 10 . In mice, this gene is located in chr19 (Accid:NG_008213.1)). Table 1 lists the samples sequenced for targeting this gene. As expected, the non-injected controls have no Cas9 reads. The sample SRR10068671 (marked with triple asterisks) has probably been mis-annotated as one with "no gRNA", since Cas9 integrations are detected in that sample. From the Cas9 integration site, the guide RNA (gRNA) for the TMC1 gene can be deduced to be "CATGGTAATGTCCCTCCTGGGGA", although this information is not yet available. The sequences for these reads are provided as extended data. As a specific example, the sequence (SRR10068639.63180.1) encodes the 26aa peptide= SPEKLLMYHHDPQTYQKLKLIMEQYG from Cas9 and is merged with the TMC1 gene ( Figure 1 ).
Cas9 integration in dystrophin
Duchenne muscular dystrophy (DMD), a genetic disorder associated with progressive muscle degeneration (dystrophy), is caused by aberrations in the dystrophin protein, located on chromosome X in humans and mice 11 . According to the data (Accid: PRJNA563918), different exons and introns have been targeted using two different variations of the Cas9 -SpCas9 and SaCas9 -which differ in certain characteristics 12 . SaCas9 does seem empirically to have more samples without any integration, but that might just be random. The sequences for these reads are provided as extended data. As a specific example, the sequence (SRR10068622.33932.1) encodes the 12aa peptide=LDATLIHQSITG from Cas9 and is merged with the DMD gene ( Figure 2 ).
AAV integration in TMC1 and DMD
The integration of AAV into the genome has already been noted 7 . This has been replicated in this study as well. The AAV genome used was Accid:MK163936.1. The reads can be found in Extended data: TMC1.aav.fa (N=5000) and DMD.aav.fa (N=14000).
Conclusions
Gene-editing based therapies provide revolutionary hope for curing many diseases. However, ensuring safety of any such endeavours must be paramount to avoid doing more harm 13, 14 . Plasmid integration is one such potential hazard 5 . Recently, Massachusetts General Hospital reported high-levels of in vivo AAV into the genome while providing sequencing data (Accid: PRJNA563918), and concluded that 'AAV integration should be recognized as a common outcome for applications that utilize AAV for genome editing' 7 . In this study, in addition to AAV, Cas9 integration is shown in the same samples. The same caveat applies to gene-therapies using CaZiTa 1 . Offtarget edits (OTE) are an important aspect of CRISPR-cas gene-editing [15] [16] [17] [18] [19] . Such integrations, found by targeting amplicon sequencing, will only get worse due to OTEs, which are hard to detect [20] [21] [22] . Another problem is pre-existing immunity to Cas9 proteins 23, 24 . This problem can be mitigated by sending the CaZiTa as protein 25 , but that would seriously restrict the use-cases, and also suffer from OTEs, large deletions, complex rearrangements and translocations 26 , or even including fragments from exosomes 27 . This is an important distinction between AAV and CaZiTa integration, since AAV integration can be tolerated (integration at chromosome breakage points 28 , though there is debate on its role in hepatocellular carcinoma 29,30 ), Cas9 integration is a huge, and unacceptable Table 1 . Integration of Cas9 into the edited gene. The paired reads are clubbed into a single file, and then uniquified. Open reading frames from these are then matched to Cas9 proteins for 10 aa, and subsequently these reads are matched to the gene of interest (TMC1 or DMD), helping identify the exact edit site. The sample SRR10068671 (marked with triple asterisks) has probably been mis-annotated as one with "no gRNA", since Cas9 integrations are detected in that sample. These integrations happen both for SpCas9 and SaCas9. From the Cas9 integration site, the gRNA for the TMC1 gene can be deduced to be "CATGGTAATGTCCCTCCTGGGGA", although this information is not yet available. CN, cortical neuron; CA: cochlea, adult. 
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